281 related articles for article (PubMed ID: 31940493)
1. FOXD3 Regulates VISTA Expression in Melanoma.
Rosenbaum SR; Knecht M; Mollaee M; Zhong Z; Erkes DA; McCue PA; Chervoneva I; Berger AC; Lo JA; Fisher DE; Gershenwald JE; Davies MA; Purwin TJ; Aplin AE
Cell Rep; 2020 Jan; 30(2):510-524.e6. PubMed ID: 31940493
[TBL] [Abstract][Full Text] [Related]
2. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
Kuklinski LF; Yan S; Li Z; Fisher JL; Cheng C; Noelle RJ; Angeles CV; Turk MJ; Ernstoff MS
Cancer Immunol Immunother; 2018 Jul; 67(7):1113-1121. PubMed ID: 29737375
[TBL] [Abstract][Full Text] [Related]
3. FOXD3 regulates migration properties and Rnd3 expression in melanoma cells.
Katiyar P; Aplin AE
Mol Cancer Res; 2011 May; 9(5):545-52. PubMed ID: 21478267
[TBL] [Abstract][Full Text] [Related]
4. Expression of the immune checkpoint VISTA in breast cancer.
Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
[TBL] [Abstract][Full Text] [Related]
5. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
Abel EV; Aplin AE
Cancer Res; 2010 Apr; 70(7):2891-900. PubMed ID: 20332228
[TBL] [Abstract][Full Text] [Related]
6. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Basile KJ; Abel EV; Aplin AE
Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
[TBL] [Abstract][Full Text] [Related]
7. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.
Xie S; Huang J; Qiao Q; Zang W; Hong S; Tan H; Dong C; Yang Z; Ni L
Cancer Immunol Immunother; 2018 Nov; 67(11):1685-1694. PubMed ID: 30128738
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
[TBL] [Abstract][Full Text] [Related]
9. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
10. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
11. VISTA Regulates the Development of Protective Antitumor Immunity.
Le Mercier I; Chen W; Lines JL; Day M; Li J; Sergent P; Noelle RJ; Wang L
Cancer Res; 2014 Apr; 74(7):1933-44. PubMed ID: 24691994
[TBL] [Abstract][Full Text] [Related]
12. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
13. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
[TBL] [Abstract][Full Text] [Related]
14. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
15. Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
Seo WI; Lee CH; Jung SJ; Lee DS; Park HY; Jeong DH; Kim W; Chung JI; Choi I
Cancer Immunol Immunother; 2021 Nov; 70(11):3113-3122. PubMed ID: 33770210
[TBL] [Abstract][Full Text] [Related]
16. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
[TBL] [Abstract][Full Text] [Related]
17. VISTA, PDL-L1, and
Tinca AC; Cocuz IG; Șincu MC; Niculescu R; Sabău AH; Chiorean DM; Szőke AR; Cotoi OS
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056382
[TBL] [Abstract][Full Text] [Related]
18. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
[TBL] [Abstract][Full Text] [Related]
19. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C; Peng W; Xu C; Lou Y; Zhang M; Wargo JA; Chen JQ; Li HS; Watowich SS; Yang Y; Tompers Frederick D; Cooper ZA; Mbofung RM; Whittington M; Flaherty KT; Woodman SE; Davies MA; Radvanyi LG; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2013 Jan; 19(2):393-403. PubMed ID: 23204132
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression.
Choi JW; Kim YJ; Yun KA; Won CH; Lee MW; Choi JH; Chang SE; Lee WJ
Sci Rep; 2020 Sep; 10(1):14372. PubMed ID: 32873829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]